Group items tagged

The UK must act swiftly to fend off competition if it wants to build the world's leading life sciences sciences hub, a new report suggests. A year on from the launch of the government's life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment. To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&D investment in the UK to build a 'stronger manufacturing and research infrastructure', alongside better investment in, access to and uptake of innovative medicines. It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government's 'Life Science Vision', which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health. The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included: £68 billion in additional GDP over 30 years, owing to increased R&D investment £16.3 billion additional annual GDP from increased pharmaceutical exports Supporting 85,000 additional jobs Up to 40 per cent decrease in disease burden across the whole UK - for areas like cardiovascular disease, mental health conditions and Cancer. Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Dekra to certify medical devices in the UK. Dekra Certification UK has joined the three current UK approved bodies, increasing the UK's capacity to process conformity assessments for medical devices to ensure safe and effective devices reach the UK public. An approved body is an organisation that has been designated by the MHRA to assess whether manufacturers and their medical devices meet the requirements set out in  the UK Medical Devices Regulations 2002. Following an appropriate assessment, the new approved body will issue relevant certification allowing manufacturers to place a UKCA marking on their products before putting them on the market. Dr Laura Squire, chief healthcare quality and access officer at the MHRA, said: "This is a major milestone in our mission to ensure patients across the UK have access to the high-quality medical devices they need to protect their health.

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

Health services in the UK today (January 4) marked the first anniversary of the deployment of the Oxford University/AstraZeneca vaccine in fight against Covid-19. Exactly a year ago, the UK became the first country in the world to administer the vaccine by jabbing Brian Pinker, 82 at Oxford University Hospital. So far, around 50 million AstraZeneca vaccines have been administered to people in the UK. Commenting on the landmark day, vaccines minister Maggie Throup said: "The Oxford-AstraZeneca vaccine is a UK success story and demonstrates what can be achieved when researchers, scientists and the government work together. "The at-cost vaccine has given billions of people around the world a way to fight back against this virus." Further, she urged people to get vaccinated to protect themselves and their families this winter.

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023. Based in Huddersfield, UK, Stephenson will report directly to STADA's Head of Western Europe and Germany, Stephan Eder. He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA's Mid-Sized European Markets.| A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies. He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland. "With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership," stated Eder.

The UK is lagging behind comparable countries when it comes to cancer survival, Cancer Research UK (CRUK) has said, calling on all political parties to make cancer a top priority in their party manifestos. While cancer survival rates in the UK have doubled over the last 50 years, the charity warned that the hard-won progress is at risk of stalling, with NHS cancer services in "crisis" and around half a million cancer cases a year projected by 2040. The charity has published an ambitious cancer plan which, if adopted by the next UK government, could dramatically improve cancer outcomes and prevent 20,000 cancer deaths a year by 2040. Called "Longer Better Lives: A Manifesto for Cancer Research and Care", the plan has been developed with the insights of cancer patients and experts from across health, life sciences, government and academic sectors, it said.

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

More than 7,000 hospitalisations and deaths in the UK could have been averted in summer 2022 if people had received their recommended COVID-19 vaccine doses, a new study published in The Lancet has revealed. The largest ever study carried out in the UK found that between a third and a half of the UK population had not had the recommended number of COVID vaccinations and boosters by summer 2022. In Northern Ireland, nearly 50 per cent of the population were under-vaccinated, while the proportion of under-vaccinated people in England was 45.7 per cent, 34.2 per cent for Scotland and 32.8 per cent Wales. Researchers from the Health Data Research UK (HDR UK) and the University of Edinburgh analysed the electronic health records of 67 million residents aged 5 and older from across the four countries during June 1 to September 30 2022.

PHOENIX UK and the British Heart Foundation has joined hands for a charity partnership to continue the ongoing commitment of improving heart health across the UK. The PHOENIX team have set the donation goal of £20,000 by June 2023 and are set to take on a range of exciting challenges over the course of the next year, such as a Tough Mudder and the Yorkshire Three Peaks challenge, all in a bid to raise funds for the heart health charity. Nigel Swift, Managing Director of Rowlands, PHOENIX UK's largest community pharmacy member organisation, commented: "We are thrilled to be partnering with The British Heart Foundation. Its lifesaving research perfectly aligns with our mission across PHOENIX UK - to enable more people to live happy and healthy lives - and so we look forward to raising vital funds and supporting the excellent work of the charity." Hayley Gough, Community Relationship Manager at The British Heart Foundation, added, "It's fantastic to see the team at PHOENIX UK commit to raising so much money for The British Heart Foundation. We can't wait to see all that they achieve and are so grateful for their fundraising efforts."

Indian multinational pharmaceutical company, Dr. Reddy's Laboratories has made its entry into the UK consumer health market with the launch of an over-the-counter allergy medication. Histallay (Fexofenadine Hydrochloride 120 mg tablets) is the company's first general sale list (GSL) product introduced in the UK market. Previously classified as a Prescription Only Medicine (POM), Dr. Reddy's Fexofenadine 120 mg is now available without prescription, under the brand name 'Histallay'. This allows people with allergic seasonal rhinitis (hay fever) to get direct access to the product via retail outlets such as pharmacies and supermarkets in the UK.

Alliance Healthcare UK has won a 'special achievement' award for its work during the Covid-19 pandemic at the Logistics UK Awards 2021. The pharmaceutical wholesaler and it's subsidiary, Alloga UK - a specialist provider of supply chain solutions for healthcare manufacturers - received the 'Special Recognition Award for Outstanding Response to Covid' at an event held in central London on Thursday, December 9, 2021 - beating off stiff competition from a number of high profile challengers. Alliance Healthcare's new managing director Marie Evans said: "I am delighted that our business and team of 6,000 colleagues have been recognised at this level for our contribution to the fight against Covid-19. Our main aim over this unprecedented period is to support the NHS, pharmacy and all UK patients, and this award is true recognition for all of that hard work and dedication." The special award category was open to an individual or organization that demonstrated an outstanding response to the pandemic in 2020 within the logistics sector and included seven other nominees including the likes of National Highways, Hermes UK and Yodel.

Teva UK has alerted the Secretary of State for Health and Social Care to the problem posed by steep energy prices. Teva's UK General Manager Kim Innes wrote to the minister seeking assurances that the distribution of medicines to patients will be safeguarded over what's likely to be a difficult winter. The problems posed by steep energy prices and the potential for power rationing is putting pharmacies under pressure from increased costs and the risk of losing power supplies as a 'non-domestic' energy user, said the company. Kim said: "In our letter to the Secretary of State we acknowledged that the government knows that medicines manufacture is strategically important and that it's a vital component in maintaining patient health." "But I wanted to make sure that the Secretary of State also realises the consequences of the energy crisis further down the supply chain - for example, the need for a pharmacy to have a fridge switched on at all times for storing cold chain products."

Moderna has joined one of the UK's leading pharmaceutical industry body, Association of the British Pharmaceutical Industry (ABPI) to expand its footprint and investment in the UK. The biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines will strengthen its footprint with the new state-of-the-art vaccine research, development and manufacturing facility in the UK. It will create valuable new jobs and build on the strength of the UK's life sciences ecosystem. The company is best known for their work during the COVID-19 pandemic and are now developing a range of mRNA-based vaccines for a number of conditions. The ABPI represents companies of all sizes who invest in discovering the medicines of the future, including some of the world's largest, most innovative, and most successful pharmaceutical firms. Darius Hughes, UK General Manager, Moderna, said: "We are delighted to join the ABPI - this alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.

McKesson UK's CEO Toby Anderson has stepped down from the role with immediate effect after over three years with the company. Toby joined McKesson UK as CEO in September 2018 moving from health & beauty retailer A.S. Watson Group, where he spent 12 years in various roles. As CEO Asia and Eastern Europe, Toby was responsible for a rapidly growing business with more than 3,300 stores - including 1,500 pharmacies. Prior to that Toby spent 11 years in a number of senior roles with J. Sainsbury, the second largest grocery retailer in the UK, his last role being Head of Online. Dominik Meüser from AURELIUS Group said: "We are extremely grateful for the commitment Toby has demonstrated over the years to help us achieve the McKesson vision of becoming the UK's leading healthcare organisation. His leadership, during a period of great uncertainty, has given us the solid foundations we can now build on to deliver sustained success in the future.

European asset management group Aurelius has completed the acquisition of McKesson UK, marking the company's fifth completed transaction in a year. McKesson UK is the parent company of a number of healthcare businesses including LloydsPharmacy, John Bell & Croyden and AAH Pharmaceuticals. It comprises four divisions and holds a substantial market share across each vertical: retail, digital, homecare and wholesale. McKesson UK's success has been underpinned by its strong LloydsPharmacy brand, its customer base and its leading commercial footprint across wholesale pharmaceuticals. Over recent years, the company has benefited from the introduction of additional services delivered across its more than 1,300 pharmacies, a growing digital offering and the ability to support the increasing trend of primary care being delivered to patients in their home.

The government has launched a consultation into radically changing the Statutory Scheme for branded medicines (known as the Statutory Scheme). The consultation comes as delicate negotiations for replacing the alternative Voluntary Scheme are underway, potentially undermining these talks, while also further damaging industry confidence in the UK as a viable place to research, launch and supply medicine. The government proposals seek to hold average revenue clawback rates under the Statutory Scheme at historic highs of between 21-27%, compared to the pre-pandemic averages of 9.4% for the Statutory Scheme (2019-2021), and 6.88% for the Voluntary Scheme (2014-2021). The accompanying cost-benefit analysis ignores any negative impact this may have on medicine supply and wrongly claims it will boost investment. The consultation comes on the heels of government data last week showing UK life sciences foreign direct investment (FDI) fell by 47% between 2021 and 2022, down by £900m year on year. This large fall in investment coincided with a rise in the main UK clawback rate under the Voluntary Scheme from 5% to 15%, and led to the UK falling from 2nd to 9th out of 18 comparator countries for life sciences FDI in 2022. The Voluntary Scheme clawback rate now sits at a record 26.5% in 2023.

Teva UK has begun replacing its existing packaging with a new design which is "clearer and easier to read". The new look is "unique, recognisable and distinctive." It "enhances safety and provides a recognisable and distinguishable pack range." One of the UK's leading generics manufacturers, Teva UK supplies more than 500 generic pharmaceutical products to retail and hospital pharmacies. The company says each product within the portfolio is distinguishable by colour, ensuring no two different packs have the same drug and strength colours and with additional product information on the side of the pack and a simplified back, it makes it even easier to identify the correct product when dispensing and supports patients when taking their medication. "Our medicines impact the lives of millions of people every day and our packaging is often the first touchpoint for our patients and our customers", said Kim Innes, general manager of Teva UK and Ireland.

Bestway operates approximately 750 pharmacies nationwide in the UK under the Well brand. In April 2023, it completed its acquisition of Lexon, which operates 46 pharmacies in the UK under the Knights Pharmacy brand, and Asurex, a wholesale perfume supplier. On 26th May 2023, CMA announced the launch of its merger inquiry. A fast-track Phase 1 investigation found that the merger could lead to a significant lessening of competition between retail pharmacies in 12 local areas located in Liverpool and North East England. The merging businesses conceded that the deal raises competition concerns in these areas and have submitted proposals to sell pharmacies within these areas to restore the competition that would otherwise be lost as a result of the deal. Colin Raftery, CMA Senior Director of Mergers, said: "Pharmacies are essential public health services, and it's vital that the loss of competition brought about by a deal like this shouldn't leave people with reduced choice or worse services when they need medical support. The CMA will now carefully consider whether the remedy put forward by Bestway will address its concerns and ensure that customers in the affected areas continue to have access to good quality chemists.

Former Prime Minister Theresa May has formally opened new offices of LEO Pharma UK and Ireland during a launch event in Maidenhead, Berkshire. The company said on Friday (June 16) that the new building, based at Foundation Park, will function as its UK and Ireland operational headquarters. LEO Pharma has been manufacturing dermatology products in the UK and Ireland for over 60 years and continues its commitment to the Maidenhead area, where it been based for 10 years. The grounds offer state-of-the-art facilities and a greener and more sustainable workplace, the company said and hoped that that strong transport connections at Foundation Park will allow for seamless international collaboration, while a range of health and wellness initiatives will contribute to employee wellbeing. This new space will enable a collaborative and flexible work environment for LEO Pharma staff, ensuring they can continue to work to improve the lives of people living with skin conditions, their families and society.

Pharmacy wholesaler PHOENIX UK is investing over £13 million to build a new state-of-the-art distribution hub in Wakefield. The 260,000 sq. ft facility is expected to be operational next year and will service community pharmacies, hospitals and dispensing doctors across the North East of England and Yorkshire. In a statement on Tuesday (July 5), PHOENIX UK said the completed hub will feature 22 dock level loading bays and seven access doors to enable the productive arrival and distribution of medical products. It will also be highly energy efficient, including the use of Solar PV on its roof. The car park will also offer 46 electric vehicle charging bays. Speaking at an official opening event held on 30 June to mark the expansion of the company's distribution capabilities, group managing director of PHOENIX Steve Anderson said: "Over the last few years, we have seen an outstanding growth in customer demand for our core services outpacing the market: Wakefield is a prime example of how we are committed to investing in the future by expanding our UK-wide operational capabilities to offer all our customers across the country the best possible service they need, want and deserve.